ClinicalTrials.gg
RecruitingNCT07077434Updated Jun 3, 2026

A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors

A Phase 1 interventional study of BMS-986504 in Advanced Solid Tumors, sponsored by Bristol-Myers Squibb. Recruiting at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability and drug levels of Navlimetostat (BMS-986504) in participants with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • MTAP
  • PRMT5
  • MRTX1719
  • CDKN2A
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have confirmed diagnosis of a solid tumor with homozygous MTAP deletion or MTAP loss detected in tumor tissue by a Sponsor-provided central test or a Sponsor pre-approved local test.
  • Participants must have unresectable or disease not amenable to curative therapies after progression on prior therapies at the time of enrollment.
  • Participants must have (ECOG) performance status of 0 or 1.
  • Participants must have presence of at least one measurable tumor lesion per 1.1 at baseline.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have prior treatment with a Protein arginine methyltransferase 5 (PRMT5) or Methionine adenosyltransferase 2A (MAT2A) inhibitor.
  • Participants must not have active or carcinomatous meningitis.
  • Participants must not have a history of gastrointestinal disease or other gastrointestinal conditions (e.g., uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.
  • Participants must not have known severe to study treatment and/or any of its .
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    BMS-986504 Arm

    Drug: BMS-986504

Interventions

  • Specified dose on specified days

    Also known as: MRTX1719

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of BMS-986504

    Time frame: Up to approximately Day 64

  2. Time to Reach Maximum Plasma Concentration (Tmax) of BMS-986504

    Time frame: Up to approximately Day 64

  3. Area Under Curve (AUC) of BMS-986504

    Time frame: Up to approximately Day 64

  4. Mean Elimination Half-life (T-HALF) of BMS-986504

    Time frame: Up to approximately Day 64

  5. Apparent Total Body Clearance (CLT/F) of BMS-986504

    Time frame: Up to approximately Day 64

  6. Apparent Volume of Distribution During the Terminal Phase (Vz/F) of BMS-986504

    Time frame: Up to approximately Day 64

Secondary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLTs)

    Time frame: Up to approximately Day 25

  2. Number of Participants With Treatment-related Adverse Events (AE)

    Time frame: Up to approximately 28 days after last dose of BMS-986504

  3. Number of Participants With all-cause AEs

    Time frame: Up to approximately 28 days after last dose of BMS-986504

  4. Number of Participants With Treatment-related Serious AEs (SAEs)

    Time frame: Up to approximately 28 days after last dose of BMS-986504

  5. Number of Participants With all-cause SAEs

    Time frame: Up to approximately 28 days after last dose of BMS-986504

  6. Number of Participants With AEs Leading to Dose Interruption

    Time frame: Up to approximately 28 days after last dose of BMS-986504

  7. Number of Participants With AEs Leading to Dose Reduction

    Time frame: Up to approximately 28 days after last dose of BMS-986504

  8. Number of Participants With AEs Leading to Treatment Discontinuation

    Time frame: Up to approximately 28 days after last dose of BMS-986504

  9. Number of Participants With AEs Leading to Death

    Time frame: Up to approximately 28 days after last dose of BMS-986504

  10. Number of Participants With Laboratory Abnormalities

    Time frame: Up to approximately 28 days after last dose of BMS-986504

07

Study locations

12 of 12 sites recruiting
  • Beijing Cancer hospital
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • lin shen, Site 0001 · Contact8601088196340
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Recruiting
    • Jing Lin, Site 0002 · Contact8613225999969
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510000, China
    Recruiting
    • Jian Xiao, Site 0010 · Contact+8613711114566
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
    Recruiting
    • shubin wang, Site 0009 · Contact13823394076
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
    Recruiting
    • Yanqiao Zhang, Site 0006 · Contact13845120210
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan 453100, China
    Recruiting
    • Yinghua Ji, Site 0011 · Contact13663030446
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    Recruiting
    • Yuping Sun, Site 0007 · Contact13370582181
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality 300060, China
    Recruiting
    • Xiuchao Wang, Site 0012 · Contact13752038814
  • Kanagawa cancer center
    Yokohama, Kanagawa 2418515, Japan
    Recruiting
    • Makoto Ueno, Site 0003 · Contact+81-45-520-2222
  • Shizuoka Cancer Center
    Sunto-gun, Shizuoka 411-8777, Japan
    Recruiting
    • Ryo Ko, Site 0008 · Contact+81-55-989-5222
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
    Recruiting
    • Jun Sato, Site 0005 · Contact+81-3-3542-2511
  • The Cancer Institute Hospital of JFCR
    Koto-ku, Tokyo 135-8550, Japan
    Recruiting
    • Shigehisa Kitano, Site 0004 · Contact+81-3-3520-0111
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jan 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Jul 22, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Jan 19, 2027
CompletionEst.
Jan 19, 2027
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07077434
Responsible party
Sponsor
First posted
Jul 22, 2025
Start date
Oct 15, 2025
Primary completion
Jan 19, 2027 (estimated)
Completion
Jan 19, 2027 (estimated)
Last update
Jun 3, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com, www.BMSStudyConnect.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navlimetostat

Start the discussion